Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Short term Debt for 7 consecutive years, with $59.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Short term Debt changed N/A to $59.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $59.4 million, a N/A change, with the full-year FY2020 number at $3.1 million, down 8.82% from a year prior.
  • Short term Debt was $59.4 million for Q2 2025 at Myriad Genetics, down from $104.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $104.1 million in Q2 2021 to a low of $59.4 million in Q2 2025.